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Recognition of Immune Reconstitution
Syndrome Necessary for Better
Management of Patients with Severe
Drug Eruptions and Those under
Immunosuppressive Therapy
Tetsuo Shiohara1, Maiko Kurata1, Yoshiko Mizukawa1 and Yoko Kano1
ABSTRACT
The immune reconstitution syndrome (IRS) is an increasingly recognized disease concept and is observed with
a broad-spectrum of immunosuppressive therapy-related opportunistic infectious diseases and severe drug
eruptions complicated by viral reactivations. Clinical illness consistent with IRS includes tuberculosis, herpes
zoster, herpes simples, cytomegalovirus infections and sarcoidosis: thus, the manifestations of this syndrome
and diverse and depend on the tissue burden of the preexisting infectious agents during the immunosuppres-
sive state, the nature of the immune system being restored, and underlying diseases of the hosts. Although IRS
has originally been reported to occur in the setting of HIV infection, it has become clear that the development of
IRS can also be in HIV-negative hosts receiving immunosuppressive agents, such as prednisolone and tumor
necrosis factor α inhibitors, upon their reduction and withdrawal. Drug-induced hypersensitivity syndrome, a
life-threatening multiorgan system reaction, is another manifestation of the newly observed IRS. Clinical recog-
nition of the IRS is especially important in improving the outcome for diseases with an otherwise life-threatening
progenosis. Clinicians should be aware of the implications of IRS and recognize that relieving the symptoms
and signs of immune recovery by anti-inflammatory therapies needs to be balanced with anti-microbial thera-
pies aiming at reducing the amplitude and duration of tissue burden of preexisting microbes.
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INTRODUCTION
Although underlying infections have been suggested
to increase infected patients’ susceptibility to severe
drug eruptions, the relationship between infections
and the development of severe drug eruptions has
not been extensively explored until the time when we
propose the intimate relationship between herpesvi-
rus infections and severe drug eruption.1,2 Since then,
however, it has become clear that closely related bidi-
rectional pathways exist in which infections and drug
allergy are involved. Thus, physicians treating pa-
tients with severe drug eruptions need to be aware of
underlying (virus) infections, particularly herpesvirus
infections, as one of the most important aspects of
management of patients with severe drug eruptions.
Because those patients often receive immunosuprres-
sive agents either early or later in the course of their
illness, a wealth of information on the interaction be-
tween herpesviruses and the immune responses
should be gathered to better manage those patient.
Immunocompetent subjects can largely control
herpesviruses, such as cytomegalovirus (CMV) and
Epstein-Barr virus (EBV), by cellular effector func-
tions based on a repertoire of memory CD4+ and
CD8+ T cells that develop and expand during lifetime.
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Defects in these T cells are associated with increased
occurrences of opportunistic infections, reactivation
of latent viruses and chronic inflammatory and auto-
immune disorders. In this setting, disease expression
has typically been understood as microbial damage
afflicted by these pathogens. However, an intriguing
aspect that has received little attention so far is that
restoration of host immunity may also have adverse
sequelae, particularly when it occurs abruptly and
rapidly. Indeed, when the timing of onset of an ad-
verse cutaneous drug reaction was carefully evalu-
ated in patients infected with HIV, the onset of a ma-
jority of the eruptions was found to be concentrated
within 6-14 days of starting highly active antiretroviral
therapy, (HAART),3 coincident with restoration of
host CD4 T-well number and reactivity. Indeed, dur-
ing the early phase of immune restoration on
HAART, a significant proportion of patients (15-25%)
develop clinical deterioration due to restoration of the
capacity to mount innate and adaptive immune re-
sponses against preexisting infectious agents. This
clinical deterioration is called immune reconstitution
syndrome (IRS). Clinical recognition of this syn-
drome is especially important in management of pa-
tients under immunosuppressive therapy, because
this syndrome develop not only in patients with HIV
infection but also in non-HIV immunocompetent
hosts, such as patients with severe drug eruptions
and those on immunosuppressive therapy, upon re-
duction or withdrawal of immunosuppressive agents
or chemotherapy. More recently, the development of
IRS has also been observed in lymphopenic and neu-
tropenic patients,4,5 and patients receiving tumor ne-
crosis factor (TNF) α inhibitions.6-8 The manifesta-
tions of this syndrome are diverse and depend on the
tissue burden of the preexisting infectious agents in-
volved under immunosuppressive conditions, the na-
ture of the immune system being restored, and un-
derlying diseases of the hosts. Because some cases
with IRS are self-limited within a week while others
are fatal or life threatening, it is difficult to predict the
prognosis and suggest potential treatment options
from the clinical manifestations in the early phase.
Thus, management of this syndrome should be de-
cided on an individual basis. In this review, we de-
scribe a variety of manifestations of IRS, particularly
those associated with severe drug eruptions, and
management options. This review also focuses exclu-
sively on the spectrum of clinical manifestations of
IRS occurring in the setting of therapy with immuno-
suppressive agents, whose clinical course is compli-
cated by the development of IRS that is usually asso-
ciated with the corticosteroid therapy on its reduction
or withdrawal. Clinical recognition of the IRS is ex-
tremely important in improving the outcome for dis-
eases with an otherwise life-threatening prognosis.
DEFINITION OF IRS
Several different terms other than IRS have been
used to describe this syndrome: they include immune
reconstitution inflammatory syndrome (IRIS), im-
mune reconstitution disease (IRD), immune recovery
disease, immune rebound illness, and steroid-
withdrawal disease. IRS is originally defined as a
paradoxical deterioration in clinical status attributable
to the recovery of the immune response following in-
stitution of HAART in HIV patients.9-11 Within 1-2
weeks of starting HAART therapy, a dramatic reduc-
tion (100-fold) in HIV RNA levels can be detected, co-
incident with the increase in circulating CD4+ T cells
with a memory phenotype in number. This rapid in-
crease in CD4+ T cell numbers is more likely to be
due to redistribution of this population to the circula-
tion rather than preferential cell proliferation. Not
only the frequency but also functions of these mem-
ory CD4+ T cells can be also restored to a clinically
relevant degree after starting HAART therapy.12 The
numerical rise of CD8+ T cells with a memory pheno-
type and naïve CD4+ T cells also occurs within 1 week
following the initiation of HAART.13
The interval between the start of HAART and the
onset of clinical symptoms or signs of IRS is highly
variable, ranging from <1 week to several months but
the majority of IRS occur within the first 8 weeks af-
ter the initiation of HAART therapy.5 In addition to
the interval, the manifestations of IRS are also widely
varied, depending on the particular infectious agent
involved and the degree of the recovery of the im-
mune system. Clinical symptoms of IRS is character-
ized by paradoxical deterioration of a preexisting, al-
though previously unrecognized, microbial infection
that is temporally associated with a decrease in the
tissue burden of the preexisting pathogens (Fig. 1):
this decrease is often reflected in paradoxical deterio-
ration of laboratory findings. Thus, the patients usu-
ally present with worsening or new clinical manifesta-
tions of a previously preexisting infection that could
be either asymptomatic or mildly symptomatic before
developing IRS: the infection would be usually unrec-
ognized by clinicians before starting HAART, or
reduction or withdrawal of immunosuppressive
agents.14 The target of restored inflammatory reac-
tions is not restricted to infectious pathogens, but
also includes inert foreign antigens such as tattoo pig-
ment15 in the case of sarcoidosis and tumor anti-
gens16 in the case of Kaposi’s sarcoma.
DIAGNOSIS OF IRS
The clinical symptoms of IRS range from a self-
limited mild disease to a severely ill, life-threatening
disease. Usually, IRS occurs as a paradoxical deterio-
ration in clinical status associated with recovery of
the immune response after initiating HAART in pa-
tients with HIV infection. Even in the absence of HIV
Immune Reconstitution Syndrome
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Fig. 1 IRS occuring after starting HAART in HIV-positive 
patients.
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infection, however, IRS has been reported to develop
on withdrawal of chemotherapy or reduction of im-
munosuppressive agents, such as prednisolone.9,17
The new onset or exacerbation of the skin diseases
known to develop as clinical manifestations of IRS,
such as sarcoidosis, has been also reported to occur
in association with TNF-α-blocking therapy in pa-
tients with rheumatoid arthritis.18,19 In view of the
fact that a similar sarcoid-like reaction occurred as a
consequence of an immune reconstitution under
HAART for HIV infection,20,21 sarcoidal lesions may
appear as clinical symptoms of IRS in these patients
during the recovery of immune responses, although
these lesions are generally perceived as undesired ef-
fects of treatment.
Unfortunately, there has been considerable confu-
sion of the definition of IRS in the literature: some
authors have used the strict criteria to define IRS,
such as a paradoxical deterioration in clinical symp-
toms attributable to recovery of the immune system
during HAART in HIV-positive patients.22 In contrast,
other authors have expanded the spectrum of IRS to
include a clinical deterioration induced by reduction
or withdrawal of immunosuppressive agents in HIV-
negative individuals. To avoid confusion, this article
includes both types of reactions, and emphasis is
placed on the IRS in HIV-negative individuals. In sum-
mary, the clinical characteristics of IRS modified from
criteria proposed by Shelburne et al.23 are as follows:
(1) paradoxical deterioration of a preexisting infec-
tion attributable to the recovery of the immune sys-
tem; (2) a decrease in viral loads with or without an
increase in CD4+ T cell counts; (3) clinical symptoms
not explained by a newly acquired infection, by the
expected clinical course of a previously recognized
infectious agent, or by side effect of therapy; and (4)
any event occurring after initiation of HAART or after
withdrawal or reduction of immunosuppressive
agents including biologics, regardless of whether pa-
tients are HIV-positive or -negative.
DRUG ERUPTIONS AS A MANIFESTATION
OF IRS
Drug-induced hypersensitivity syndrome (DIHS) is a
life-threatening multiorgan system reaction caused
by a limited number of drugs: they include car-
bamazepine, phenytoin, phenobarbital, zonisamide,
alopurinol, dapsone, salazosulfapyridine and mex-
iletine.1,2,24-31 However, this syndrome has several
unique clinical features that cannot be solely ex-
plained by drug antigen-driven oligoclonal expan-
sions of T cells, which have been implicated in the
pathogenesis of other drug eruptions. They include a
paradoxical deterioration of clinical symptoms, fre-
quent flare-ups and a step-wise development of sev-
eral organ system failures after withdrawal of the
causative drugs,26,30 and unexplained cross-reactivity
to multiple drugs with structures totally different
from the original causative drugs.26,30 Close clinical
similarities between DIHS and infectious mononu-
cleosis suggested an additional role of viral infec-
tions.1,2,26 Indeed, our recent studies have demon-
strated that several herpesviruses including herpesvi-
rus 6 (HHV-6), HHV-7, EBV and CMV can be reacti-
vated during the course of this syndrome in a sequen-
tial order as in graft-versus-host disease.29 However,
several questions have been raised as to why HHV-6
reactivation, which is used as a specific marker for
this syndrome,25 occurs generally 2-3 weeks after the
onset of this syndrome and why particular virus could
not be detected coincident with the onset of severe
symptoms. Based on these findings, reactivations of
these herpesviruses observed in DIHS was generally
thought to be the consequence of disease,24 contrary
to our hypothesis30: according to our hypothesis, re-
activations of herpesviruses would represent the ac-
tual early events that trigger activation of drug
antigen-specific T cells: however, this event would oc-
cur in an unrecognized fashion far before onset of
clinical symptoms. In view of the observations that
paradoxical worsening of clinical symptoms associ-
ated with reduction in viral loads is typically observed
after withdrawal of the causative drug at onset of
DIHS,2,30 it is attractive to suppose that DIHS is a
manifestation of the newly observed IRS (Fig. 2).
These clinical observations may be explained by as-
suming that the rapid restoration of pathogen-specific
immunity would reduce viral loads at onset, thereby
rendering them undetectable in the blood.
In order to expand the spectrum of IRS to include
DIHS, it was important to know to what extent DIHS
resembles IRS by demonstrating similarities between
both conditions. We analyzed a total of 12 patients (6
male, 6 female; age range 25-70 years, mean age
46.5 ± 15.3 years), who admitted to our Dermatology
Department from 2001 to 2006 and met the criteria
for DIHS.25 Clinical status of these patients on day 3-4
was defined as a paradoxical deterioration despite
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Fig. 2 DIHS is another manifestation of the newly observed IRS. The causative 
drugs of DIHS have immunosuppressive properties in common2,26,30 and their pro
tracted use results in the immunosuppressive state, thereby causing the increase 
in viral loads in an unrecognized fashion. Upon withdrawal of these drugs, antiviral 
immune responses are rapidly restored, thereby causing immunopathology and 
the reduction in viral loads.30
Immune recovery
(e.g. CD4+ T cells)
Clinical symptoms
e.g. Viral load
Unrecognized
viruses
Causative drugs 
with immunosuppressive
function
A B
Fig. 3 Paradoxical deterioration of skin lesions in IRS observed after withdrawal of the 
causative drug. This patient with DIHS exhibited prominent paradoxical deterioration of fa
cial edema and erythema (B) 4 days after the withdrawal, as compared with those at the 
initial presentation (A).
withdrawal of the causative drug, when the extent of
skin involvement as evaluated by the body surface
area (BSA) was 2 times more than their initial presen-
tation; and an increase in their body temperature
>1℃ from that at their initial presentation. According
to this definition, 8 out of the twelve patients exhib-
ited a paradoxical deterioration in clinical status de-
spite withdrawal of the causative drug (Fig. 3). In the
remaining four patients, oral prednisolone had been
started at a dose of 40-60 mgday at their initial pres-
entation, because their skin lesions had rapidly pro-
gressed, in a few days before presentation, to over
Immune Reconstitution Syndrome
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Table 1 Reported clinical ilness consistent with IRS in 
HIV-negative hosts
Mycobacterium avium complex infection
Tuberculosis
Cryptococcosis †
Herpes simplex †
Herpes zoster †
Hepatitis C virus infection
Hepatitis B virus infection
Cytomegalovirus infection †
Kaposi sarcoma
Sarcoidosis
Graves disease
Hashimoto thyroiditis †
Drug-induced hypersensitivity syndrome
 † Infectious and autoimmune diseases often observed during 
the course of drug-induced hypersensitivity syndrome or long af-
ter its resolution.
60% or more of BSA, probably due to their earlier tim-
ing of withdrawal of the causative drugs: unfortu-
nately, however, the exact time frames between with-
drawal of the causative drug and their initial presenta-
tion was not available in these patients. In these pa-
tients, oral prednisolone given as initial therapy had a
rapid response. In the eight patients with paradoxical
deterioration in clinical symptoms, 5 cases that in-
itially failed to respond to oral predonisolone subse-
quently improved with intravenous immunoglobulin
(IVIG, 0.1 gkgday, 5-10 days).
According to the diagnostic criteria for IRS pro-
posed by Shelburne et al.,23 an increase in CD4+ T-
cell numbers is a prerequisite for the diagnosis of
IRS. This prompted us to investigate whether an in-
crease in CD4+ T-cell numbers could be observed and
onset in these patients. Because CD4+ T-cell numbers
before onset of DIHS were not available in the vast
majority of patients, we sequentially analyzed lym-
phocyte subsets from the 10 patients at various time
points after their initial presentation and compared
CD4+ T-cell numbers at onset with those on several
occasions after onset. As previously descried,31 a pro-
found decrease in CD19+ B-cell numbers and CD56+
NK-cell numbers were observed at their initial pres-
entation. In contrast, CD4+ T-cell numbers initially in-
creased in 9 of the 10 patients; they were gradually
declined, reaching normal values by 2 months after
onset. According to the original definition,23 an in-
crease in CD4+ T-cell numbers is diagnostic of IRS
and can typically be detected within 1-2 weeks of
starting antiretroviral therapy in HIV-infected pa-
tients. Consistent with this, our sequential analyses
showed that the initial increase in CD4+ T-cell num-
bers was seen in many, if not all, patients with DIHS,
followed by the subsequent decrease coincident with
improvements in clinical status. In some patients, a
concomitant increase in CD8+ T-cell numbers was
also noted. These alterations in lymphocyte subsets
during the observation period were not related to our
use of oral prednisolone for the treatment of DIHS,
because similar alterations were observed in patients
who never received prednisolone. The degree of the
increase in CD4+ T-cell numbers best correlated with
the severity of clinical symptoms, such as the extent
of skin lesions at the acute stage.
SKIN DISEASES AS MANIFESTATIONS OF
IRS
The occurrence or recurrence of various infectious
diseases and autoimmune diseases has been reported
in many patients recently starting HAART, those with
severe drug eruptions or those receiving immunosup-
pressive therapy on a reducing dose or withdrawal of
immunosuppressive agents, as shown in Table 1.
HERPES ZOSTER
Herpes zoster (HZ) is caused by reactivation of latent
varicella zoster virus (VZV) within a sensory gan-
glion. HZ is the most common manifestation of IRS in
HIV-infected individuals and it counted for 40% of IRS
events in one cohort32: the incidence of HZ is higher
than immunocompetent healthy individuals; and the
incidence is relatively consistent regardless of the
stages of HIV infection.33 HZ has been reported to oc-
cur two- to five-fold more frequently in HIV-infected
patients treated with HAART than in those not receiv-
ing HAART.34-36 The timing of HZ after the initiation
of HAART has been highly variable, ranging from 4
weeks to 103 weeks.34-36 Onset of HZ in 50% of cases
occurred within the first 4 weeks after initiation of
HAART and 86% occurred between week 4 and 16.34
There was a significant increase in CD8+ T cell num-
bers and percentages concurrent with HZ episodes,
as well as reduction of HIV viral load,35 while in other
report, a marked increase in CD4+ T cell numbers,
but not CD8+ T cells, was also observed during HZ
episodes.36 These results indicate that vigorous ex-
pansion of CD4+ T cells may contribute to either the
development of IRS or the decrease in HIV viral load.
This effect may be mediated by IL-6 or IFN-α, both of
which have been shown to play important roles in IRS
events.37,38 Alternatively, in view of tropism of VZV
for CD4+ T cells with a skin-homing phenotype,39,40
expansion of CD4+ T cells may be directly responsi-
ble for the development of HZ in this setting.
HIV-negative patients undergoing bone-marrow or
organ transplantation and treated with immunosup-
pressive agents including corticosteroids, are also at
increased risk of developing HZ as a manifestation of
IRS. The timing of HZ after starting these treatments
was more variable than in those treated with HAART.
As compared with the setting of HAART-induced im-
mune reconstitution, it is difficult to estimate when
immune reconstitution occurs after starting these
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Fig. 4 HZ developing 2 months after the final course of chemotherapy. The onset of HZ is coincident 
with the restoration of immune responses as evidenced by the increase in neutrophil and lymphocyte 
counts.
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treatments. Although these treatments themselves
are thought to place some patients at increased risk
of developing HZ, it may be noted that may if not all
patients develop HZ after withdrawal or tapering dose
of these immunosuppressive agents if the timing of
HZ is carefully checked in relation to these treat-
ments. Unfortunately, however, literature review on
this issue is not possible at this time, because little at-
tention has been focused on the timing of HZ in rela-
tion to these treatments. Although our series was not
large enough to demonstrate the exact timing of HZ
onset after the start of these treatments, we found
that most cancer patients (35 cases) developed HZ 1
to 3 months after the final course of chemotherapy
(Fig. 4) and that patients with rheumatoid arthritis or
lupus developed HZ as well, 1 to 3 weeks after taper-
ing dose of oral prednisolone (Kurata, M. et al., un-
published data). Because recent studies have found
no significant outcomes, such as HZ, associated with
short-term use of prednisolone in advanced HIV in-
fection,41 short-term predonisolone therapy is un-
likely the major cause of HZ in this setting. Interest-
ingly, in the most HIV-negative cases of HZ occurring
upon withdrawal or reduction in immunosuppressive
agents, the rash generally appears on the trunk and
extremities, but not on the face and head. Most cases
had uncomplicated dermatomal HZ and none had se-
vere complications, such as fatal disseminated HZ.
Thus, VZV reactivation in the setting of immune re-
constitution may elicit only a mild inflammatory reac-
tion. Indeed, in the setting of DIHS, patients usually
manifest a mild from of HZ before and after onset of
DIHS: the onset of HZ is usually 2 to 3 months after
onset of DIHS and often associated with the reduc-
tion of corticosteroids. There have been case reports
of nondermatologic zoster, zoster sine herpete: they in-
clude stromal keratitis and iritis without concurrent
HZ skin lesions. In addition, rare association of se-
vere VZV vasculopathy involving the central nervous
system in the setting of IRS has been also reported.
HERPES SIMPLEX
Frequent reactivations of herpes simplex virus (HSV)
serve to increase the level of HIV viral load, with im-
plications for HIV transmission and disease progres-
sion.42 Although HAART is theoretically thought to
have a beneficial effect on HSV reactivation, it re-
mains to be established whether the incidence and
severity of HSV disease could be decreased after
HAART. Ratnam and colleagues43 reported that HSV
accounted for 50% of all IRS events and the onset to
be a median of 12 weeks after starting HAART. How-
ever, reports regarding the timing and incidence of
HSV onset after starting HAART have been diverse
depending on the definition of IRS. In this regard,
they used strict criteria for IRS: they defined HSV dis-
ease as a manifestation of IRS only when the fre-
quency, severity, or poor response to treatment was
significantly increased during the 6 months after
starting HAART. Severe cases with extensive perianal
lesions and fever, severe hemorrhagic nasolabial le-
sions, or encephalis, respectively, have been also re-
ported after starting HAART.43,44 Some cases have
run a chronic course. The clinical course of these
cases is likely to indicate that restoration of immune
responses to HSV may remain partial despite suc-
cessful control of HIV replication45 thereby causing
an imbalance between autoreactive and autoregula-
tory lymphocytes: this imbalance could result in the
development of severe lesions.
Neurologic complications probably induced by re-
activations of HSV or HHV-6 have been also reported
to occur during the course of DIHS. Masaki et al. re-
ported a patient with allopurinol-induced DIHS who
developed encephalitis after the reduction of corti-
costeroids.46 The cerebrospinal fluid (CSF) polym-
erase chain reaction (PCR) assay was positive for
HHV-6 in this patient. We also described a patient
Immune Reconstitution Syndrome
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Fig. 5 CMV reactivation coincident with expansions of circulating CD4+ T cels in a HIV-
negative patient with DIHS.59
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with phenobarbital-induced DIHS who revealed syn-
drome of inappropriate secretion of antidiuretic hor-
mone (SIADH) associated with limbic encephalitis.47
However, no viral DNA was identified by PCR in CSF
specimens repeatedly collected after the onset of en-
cephalitis. Because of suspected herpetic encephali-
tis, empirical high-dose aciclovir (10 mgkg every 8h
IV) was started for 7 days with some effects. Al-
though it remains to be determined whether SIADH
and limbic encephalitis commonly have developed as
a result of HHV-6 or HSV reactivation in our case, our
failure to defect viral DNA in CSF may be explained
by partial restoration of HHV-6 or HSV-specific immu-
nity during the course of DIHS: immune reconstitu-
tion to HHV-6 or HSV in the central nervous system
was the presumed cause. Interestingly, a similar un-
usual presentation of limbic encephalitis caused by
HHV-6, associated with hyponatremia, has been pre-
viously described in several hematopoietic cell trans-
plant recipients who developed a generalized skin
rash suggestive of graft-vs.-host disease (GVHD).48
CYTOMEGALOVIRUS
CMV usually persists in a latent asymptomatic state
after initial infection in the vast majority of individu-
als. Overt CMV disease predominantly induced by re-
activation of latent CMV can be produced in an im-
munosuppressive host, such as organ transplant re-
cipients, patients with AIDS, and those receiving im-
munosuppression agents. CMV disease can usually
present as visceral diseases ranging from pneumonia
to widely disseminated diseases,49,50 cutaneous mani-
festations are rare and very variable, including ulcers,
vesicles, purpuric macules, verrucous lesions, pru-
rigo nodularis-like lesions, erythematous and crusted
papules and digital infarct, regardless of whether it is
specific or nonspecific.51-54 These lesions occur as the
late systemic manifestation of CMV infections and
usually portend a fatal course.55,56
Regarding CMV infection as a manifestation of IRS
in the setting of HIV infection, CMV retinitis is a com-
mon complication at the late stage.23 The severity of
clinical symptoms is far greater than that seen in the
setting of non-HIV infection, and therefore it was
termed “immune recovery retinitis”.57 CMV infection
in the setting of IRS is also characterized by the sys-
temic nature and cutaneous manifestations have been
rarely reported. Qazi and colleagues,58 however, re-
ported a rare case of extensive CMV cutaneous ul-
ceration occurring in a patient with HIV infection 3
months after starting HAART. Because the onset of
CMV ulceration was associated with an increase in
CD4+ T cell counts and a decrease in HIV viral load
and the patient had a history of CMV retinitis, these
features have fulfilled the criteria for IRS. This case
was very unique in that the extensive CMV ulceration
involved the back, both arms, and the left ear, instead
of localized in the perianal region; that the patient had
received maintenance prophylaxis with oral ganci-
clovir before the onset of the extensive CMV ulcera-
tion, and that the CMV ulcerations improved with ad-
dition of intravenous methylprednisolone to the treat-
ment regimen. These features are consistent with
CMV infection as a manifestation of IRS and are dif-
ferent from that occurring in immunocompromised
patients not receiving HAART.
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We have recently reported two HIV-negative pa-
tients with DIHS, who developed cutaneous CMV ul-
cers on the trunk (Fig. 5).59 This event was eventu-
ally followed by the development of gastrointestinal
manifestations which were fatal in one patient but not
in another. In one patient, 74-year-old man, the erup-
tion began suddenly, and the papules were distrib-
uted mainly over the upper back. There were no con-
comitant perianal ulcers. Within 2-3 days, the lesions
became centrally ulcerated with a rim of erythema:
the clinical features of the established lesions mim-
icked those of Degos’ disease. Examination of a bi-
opsy specimen of the ulcer showed eosinophilic in-
tranuclear ‘owl’s eye’ inclusions surrounded by a
clear halo in the upper dermis: the CMV infection
was confirmed by immunohistochemistry. Because of
no improvement in his ulceration on oral predniso-
lone prescribed for drug eruptions, intravenous im-
munoglobulin (IVIG) was started with significant im-
provement in his ulcerations. Treatment with intrave-
nous ganciclovir was also added and oral predniso-
lone was gradually tapered. Although the ulcers
showed gradual signs of healing, the patient devel-
oped CMV enterocolitis. He eventually died of respi-
ratory failure. In another case (81-year-old man),
scratch dermatitis-like erythema developed on the
back after 2 week of therapy with IVIG. Ulcerated
erythematous papules were also detected on the
shoulder. Histologic examination of the papules
showed a few cytomegalic endothelial cells harboring
eosinophilic intranuclear inclusions. The CMV infec-
tion was confirmed by immunohistochmistry. On the
same day, he developed CMV gastritis. The patient
was successfully treated with intravenous gancy-
clovir. Because it is widely believed that cutaneous,
CMV disease arises from reactivation of a local latent
virus or by autoinoculation in periorificial areas by
faecal, urinary or salivary shedding of CMV,60 CMV
ulcers limited to the unusual sites such as trunk
would go unrecognized. These cases indicate that a
high index of suspicion and intervention may de-
crease morbidity and the need for monitoring of
CMV reactivation even in immunocompetent pa-
tients, particularly when unexplained ulcers suddenly
develop in patients with severe drug eruptions. In
these cases, drug eruptions per se would provide a ba-
sis for immune reconstitutions as an etiologic factor.
TREATMENT OF IRS
Before starting treatment, it is important to exclude
the possibility that paradoxical worsening of clinical
symptoms of a preexisting infection regarded as
signs of IRS could be a result of inadequate antimicro-
bial therapy or superinfection with other microorgan-
isms,9 because some individuals with IRS worsen
clinical symptoms as a result of sub-optimal immune
function associated with inadequate antimicrobial
therapy. Although corticosteroids are most fre-
quently used agent, there have not been clear guide-
lines for how patients with IRS are treated with corti-
costeroids. Because a mild form of IRS responds to
specific treatment for the underlying pathogens, anti-
inflammatory therapies are not generally required:
thus, the management of patients with IRS is pre-
dominantly supportive. In patients with severe forms
of IRS, however, anti-inflammatory therapies in addi-
tion to anti-microbial therapies are necessary to ame-
liorate clinical symptoms due to overshooting of im-
mune recovery. Nevertheless, the need for relieving
the symptoms and signs of immune recovery by anti-
inflammatory therapies should be balanced with anti-
microbial therapies aiming at reducing the amplitude
and duration of tissue burden of preexisting mi-
crobes.
Corticosteroids have been the mainstay of treat-
ment for IRS and are the only treatment for which
clinical trial data exit.61 Significant benefit was dem-
onstrated in terms of symptom improvement in a
range of infectious diseases: they include bacterial
meningitis, tuberculous meningitis, pneumocystic
pneumonia, microbacterial avium complex, leprosy,
cryptococcosis, and Pneumocystis jiroveci.61 Indeed,
systemic corticosteroids gave promising results in
terms of ameliorating vigorous restoration of immune
responses to pathogens during the course of DIHS,
as a manifestation of IRS. However, once systemic
corticosteroids have started, drug dose should be re-
duced gradually even upon resolution of clinical
manifestations in IRS, particularly in DIHS, because
patients with DIHS are at greater risk of subse-
quently developing the wide spectrum of IRS ranging
from CMV disease to autoimmune diseases29,62,63 and
the use of systemic corticosteroids represents an im-
portant factor that increases the risk of disease pro-
gression to full manifestations of IRS upon the with-
drawal or reductions. Given the high risk of se-
quaelae from CMV reactivation in patients with
DIHS, the direct anti-CMV medications with stepwise
withdrawal of corticosteroids may help to avoid dis-
ease progression to full manifestations of IRS.
TNF-α plays a critical role in the initial host re-
sponse to infection. Although it has been proposed
that TNF-α inhibitors may be effective in the treat-
ment of IRS, patients treated with TNF-α inhibitors
have been reported to have developed IRS during
anti-tuberculous treatment64-67: active tuberculosis oc-
curred after a medium duration of 3.5 months of in-
fliximab use. Mirmirani et al. reported that a HIV-
infected patient developed active sarcoidosis soon af-
ter starting HAART.68 Indeed, the histological hall-
mark of IRS is granuloma formation, which is medi-
ated by Th1 cells69 and the formation of granulomas
is often observed in the late lesion of DIHS. Thus,
TNF-α inhibitors could induce or precipitate sarcoi-
dosis as a manifestation of IRS while they may benefit
some patients with IRS.
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CONCLUSION
Maintaining a fine balance between host and infec-
tious agents, but not eradication of the latter, is the
therapeutic goal of IRS. Although corticosteroids or
TNF-α inhibitors may improve the clinical symptoms,
one needs to be cautious in determining when a ther-
apy that would abrogate the immune response to the
infectious agents can be initiated.
Prompt recognition of DIHS as a new manifestation
of IRS could help the physicians to determine the ap-
propriate next step when a complex sequence of
events described above occurs, thus improving the
morbidity and mortality of otherwise life-threatening
disease. Future studies of the appropriate manage-
ment of IRS will need to establish a diagnostic tool
that can distinguish whether clinical symptoms
worsen as a result of an overwhelming inflammatory
response or they do as a consequence of expansions
of an opportunistic organism induced by sub-optimal
immune function.
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